Antibody-Drug Conjugates
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
ADCs: Global market intelligence for investors & BD. Stay ahead on novel payloads, linker tech, and clinical trial updates for antibody-drug conjugates.
Showing 1–12 of 13 articles
Quick answer
NovaPharmaNews Antibody-Drug Conjugates hub for FDA covers 13 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Friday Five: ASCO Takeaways, ADA Focus, China Deals & More – Clinical Trials
ADC Specialist Sinks on Safety Concerns: What Pharma Teams Need to Know
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
ASCO ‘26: Bispecifics, ADCs, and the RAS Revolution Reshape Oncology
AbbVie's Decnupaz Secures FDA Approval for Rare Blood Cancer
Pharma Partnering US: $77.3B Licensing Deals in Q1 2026
Aclaris Therapeutics ATI-052 Shows Promising 45-Day Half-Life in Phase 1a Trial Results
Tovecimig Shows 56% Reduction in Cancer Progression Risk in Biliary Tract Cancer Trial
Oncology Data Landscape 2026: Key Trends & Upcoming Readouts
AACR 2024: Oncology News & Key Takeaways - Day 1
ANVISA Guidelines for Antibody-Drug Conjugates: What You Need to Know
Antibody-Drug Conjugates MEA: Pricing, Access & Adoption Insights 2024
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.